HaemoneticsSTU:HAZ 25 FCF Yield % is 7.64 as of Jul. 01, 2026, which is 207% above its 10-year median of 2.49. GuruFocus rates STU:HAZ with a GF Score™ of 25/100 and a GF Value™ of €74.16. The stock has 4 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Haemonetics ranks better than 90.54% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Haemonetics's FCF Yield % or its related term are showing as below:
STU:HAZ'
s FCF Yield % Range Over the Past 10 Years
Min: 0.55 Med: 2.49 Max: 12.13
Current: 7.64
During the past 13 years, the highest FCF Yield % of Haemonetics was 12.13%. The lowest was 0.55%. And the median was 2.49%.
STU:HAZ's FCF Yield % is ranked better than 90.54% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: -0.405
vs STU:HAZ: 7.64
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Haemonetics FCF Yield % Related Terms
Haemonetics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Haemonetics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:HAZ vs ITGR, IRTC, ESTA: FCF Yield % Comparison
For the Medical Devices subindustry, Haemonetics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Haemonetics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (STU:HAZ) has a FCF Yield % of 7.64 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haemonetics and its competitors. This is 207% above median its historical median of 2.49. Over the past decade, Haemonetics' FCF Yield % has ranged from 0.55 to 12.13. According to the industry distribution chart, Haemonetics ranks #81 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 9.5%.
Is Haemonetics' FCF Yield % too high?
Haemonetics' current FCF Yield % of 7.64 is 207% above median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 12.13. Based on the distribution chart, Haemonetics ranks #81 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Haemonetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' FCF Yield % compare to ITGR and IRTC?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #81 out of 856 companies for FCF Yield %. This places Haemonetics in the top 10% of its industry — outperforming the majority of peers. Historically, Haemonetics' own FCF Yield % has ranged from 0.55 to 12.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Haemonetics and its competitors. Haemonetics's current FCF Yield % is 7.64, which is 207% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current FCF Yield % of 7.64. The stock's GF Value™ is €74.16, compared to a current price of €65.50 — trading 11.7% below its estimated fair value. The current FCF Yield % is 7.64, which is 207% above median its 10-year median of 2.49. Haemonetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current FCF Yield % is 7.64 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (STU:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued.
The current stock price of €65.50 is trading 11.7% below its estimated GF Value™ of €74.16.
Key valuation signals for STU:HAZ:
FCF Yield %: 7.64 (207% above median its 10-year median of 2.49)
GF Value™: €74.16 vs. price of €65.50 (11.7% below fair value)
No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
25GF Score
Get the complete analysis for STU:HAZ
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HAZ has been successfully added to your 
